111 filings
S-3ASR
RLAY
Relay Therapeutics, Inc.
6 Aug 24
Automatic shelf registration
5:23pm
10-Q
2024 Q2
RLAY
Relay Therapeutics, Inc.
Quarterly report
6 Aug 24
4:15pm
8-K
RLAY
Relay Therapeutics, Inc.
6 Aug 24
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
4:10pm
8-K
RLAY
Relay Therapeutics, Inc.
16 Jul 24
Termination of a Material Definitive Agreement
4:15pm
8-K
RLAY
Relay Therapeutics, Inc.
6 Jun 24
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
8:00am
8-K
nbv01nzjs00ik16tx0e
3 Jun 24
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
2uo4k2b nf
2 May 24
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
4:10pm
ARS
uvvgc4hi4 w2
23 Apr 24
Annual report to shareholders
4:15pm
DEFA14A
dod8c4ut
23 Apr 24
Additional proxy soliciting materials
4:10pm
S-8
g5oii 3ctf7iqa9ya0
22 Feb 24
Registration of securities for employees
4:34pm
8-K
op3i3frux
22 Feb 24
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:10pm
424B7
g2blz
10 Jan 24
Prospectus with selling stockholder info
9:22am
D
u35e5e02nvorksly3
10 Jan 24
$30.00 mm in equity, sold $30.00 mm, 1 investor
9:14am
8-K
9zqxfa
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
424B7
1m2i4
16 Nov 23
Prospectus with selling stockholder info
4:16pm
8-K
3gpc73
2 Nov 23
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:10pm